Study at a glance
Which DNA sections help control vitamin D activation in mouse kidneys?
Researchers used genetically modified mice to study control of vitamin D activation in the kidneys. They removed two different sections of DNA that control Cyp27b1, the gene for an enzyme used in the final activation step. They then tested the effects of parathyroid hormone, another hormone called FGF23, and active vitamin D.
What happened when the first section was removed?
The gene’s usual activity fell by about 95%, and parathyroid hormone could no longer increase it normally. These mice developed low calcium and phosphate, very high parathyroid hormone and extremely low FGF23. The result showed that this DNA region was necessary for the normal response to parathyroid hormone in the tested mice.
How did the second change differ?
Removing the other section reduced usual gene activity by about 75%. parathyroid hormone could still increase activity, but FGF23 and active vitamin D could no longer reduce it normally. These mice maintained calcium and phosphate much more effectively. Other parts of the control system partly made up for the disruption. Relatively normal mineral levels did not mean that the underlying controls were normal.
Can these results from mice guide vitamin D treatment in people?
The study tested large, deliberate DNA changes in mice. It does not establish ordinary human responses, treatment targets or supplement requirements. Calcium and phosphate were mainly measured as parts of the resulting mineral balance. They were not tested as direct controls of the DNA regions in the same way as the hormones. The findings describe how this system can work in mice, not how to set personal treatment.
Read the full article below ↓This study examined how the kidney regulates the final activation step of vitamin D metabolism. Using genetically modified mice, the researchers investigated control of Cyp27b1, the gene encoding CYP27B1, which converts 25-hydroxyvitamin D3 [25(OH)D3] to the active hormone 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. They identified distinct kidney-specific regulatory regions involved in stimulation by parathyroid hormone (PTH) and suppression by fibroblast growth factor 23 (FGF23) and 1,25(OH)2D3. The study also showed how disruption of this regulatory machinery affected the wider calcium: phosphate and vitamin D homeostatic system.
For the complete methodological analysis and evidence boundaries, see Renal Vitamin D Activation: Full Evidence Review.
What question did this study investigate?
The researchers wanted to understand how endocrine signals regulate renal Cyp27b1 expression and therefore control the final activation step of vitamin D metabolism.
The study focused particularly on PTH, FGF23 and 1,25(OH)2D3. PTH stimulates renal Cyp27b1 expression, whereas FGF23 and 1,25(OH)2D3 suppress it. The researchers investigated whether these different hormonal effects depend on distinct regulatory regions associated with the Cyp27b1 gene.
The wider physiological question was how disruption of this regulatory system would affect vitamin D metabolism and calcium: phosphate homeostasis in living animals.
What was studied?
Study design: Primary in-vivo and molecular experimental study using genetically modified mouse models.
Experimental system: Wild-type mice and genetically modified mice carrying targeted deletions of kidney-specific regulatory regions associated with Cyp27b1.
Interventions: Treatment with PTH, FGF23 or 1,25(OH)2D3, together with targeted deletion of genomic regulatory regions involved in renal Cyp27b1 expression.
Primary relevant outcome: Regulation of renal Cyp27b1 expression and the physiological consequences of disrupting that regulation.
How was the study carried out?
The researchers first examined the genomic region surrounding Cyp27b1 to identify kidney-specific regulatory elements. They then deleted selected regulatory regions in mice so that their functions could be tested experimentally.
Two genetically modified models were particularly informative. M1-IKO mice lacked a regulatory region within Mettl1, while M21-IKO mice lacked a different regulatory region within Mettl21b.
The researchers then tested how renal Cyp27b1 responded to PTH, FGF23 and 1,25(OH)2D3. They also measured vitamin D metabolites, calcium, phosphate, PTH, FGF23 and other components of vitamin D metabolism, allowing molecular regulation to be examined alongside its wider physiological consequences.
What did the researchers find?
The study showed that different parts of the kidney-specific regulatory system controlled different hormonal responses.
In M1-IKO mice, basal renal Cyp27b1 expression was reduced by approximately 95%, and the normal stimulatory response to PTH was lost. These animals developed major disturbances in vitamin D and mineral homeostasis, including hypocalcaemia, hypophosphataemia, markedly elevated PTH and extremely low FGF23.
In M21-IKO mice, basal Cyp27b1 expression was reduced by approximately 75%. However, these animals retained responsiveness to PTH while losing normal suppression of Cyp27b1 by FGF23 and 1,25(OH)2D3.
Despite this substantial molecular disruption, M21-IKO mice maintained calcium and phosphate concentrations much more effectively than M1-IKO mice. This demonstrated the capacity of the wider endocrine system to compensate for some disturbances in vitamin D activation.
What does this study support?
The study provides strong mechanistic evidence that renal vitamin D activation is actively regulated rather than functioning as an uncontrolled conversion step. PTH stimulation and FGF23/1,25(OH)2D3 suppression of Cyp27b1 depended on different components of a kidney-specific genomic regulatory system.
The resulting physiological changes also show that regulation of vitamin D activation is integrated with calcium and phosphate homeostasis. Changes in renal Cyp27b1 regulation affected PTH, FGF23, vitamin D metabolism and mineral balance as parts of an interconnected system.
What does this study not establish?
The study does not establish that calcium, phosphate, PTH and FGF23 all act directly and equivalently on Cyp27b1. PTH, FGF23 and 1,25(OH)2D3 were experimentally tested as direct endocrine regulators of renal Cyp27b1 expression. Calcium and phosphate were principally measured as components of the wider homeostatic system.
The findings therefore support an integrated calcium: phosphate: PTH: FGF23 framework surrounding renal vitamin D activation without demonstrating the same molecular mechanism for every component.
The study also does not establish human regulatory thresholds, clinical target concentrations or vitamin D supplementation requirements. It was a mechanistic mouse experiment rather than a human clinical study.
What are the main limitations?
The principal limitation is that the experiments were conducted in genetically modified mice. The findings provide powerful in-vivo mechanistic evidence, but the exact genomic architecture and magnitude of endocrine responses cannot automatically be assumed to be identical in humans.
The targeted genomic deletions were also deliberately substantial experimental disruptions. They are useful for identifying which regulatory regions are necessary for particular hormonal responses, but the resulting phenotypes should not be interpreted as ordinary physiological variation.
Finally, apparently normal mineral concentrations do not necessarily indicate normal underlying regulation. The M21-IKO animals retained relatively normal calcium and phosphate despite major alterations in Cyp27b1 regulation, illustrating the importance of compensatory endocrine mechanisms.
Why this matters within vitamin D physiology
The final activation of vitamin D is not simply a chemical conversion that proceeds at a fixed rate. Renal CYP27B1 sits within a regulated endocrine network that responds to signals reflecting the body’s mineral and vitamin D physiology.
This study demonstrates that PTH-driven stimulation and FGF23/1,25(OH)2D3-driven suppression can be separated at the level of the genomic machinery controlling renal Cyp27b1. Disrupting those controls can then propagate through vitamin D metabolism and calcium: phosphate homeostasis.
The study therefore helps explain how the kidney functions as a regulated site of vitamin D activation rather than merely as a passive location for the final hydroxylation reaction.
For the broader physiology, see Vitamin D Activation.
For the enzyme pathways involved in vitamin D activation and degradation, see Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).
For the complete analysis of this study, see Renal Vitamin D Activation: Full Evidence Review.
Primary source and publication details
Meyer MB, Benkusky NA, Kaufmann M, Lee SM, Onal M, et al.
A kidney-specific genetic control module in mice governs endocrine regulation of the cytochrome P450 gene Cyp27b1 essential for vitamin D3 activation.
Journal of Biological Chemistry. 2017;292(42):17541 to 17558.
PMID: 28808057
PMCID: PMC5655528
DOI: 10.1074/jbc.M117.806901
View the verified primary source
Related reading
Aerobic exercise prevents renal osteodystrophy via irisin-activated osteoblasts
Renal osteodystrophy is commonly seen in patients with chronic kidney disease (CKD) due to disrupted mineral homeostasis.
Original paper ↗Read more →Bone Histomorphometry and 18F-Sodium Fluoride Positron Emission Tomography Imaging: Comparison Between only Bone Turnover-based and Unified TMV-based Classification of Renal Osteodystrophy
In unified turnover-mineralization-volume (TMV)-based classification, the whole histopathological picture was evaluated and the range for normal turnover was set accordingly.
Original paper ↗Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss
Phosphate overload contributes to mineral bone disorders that are associated with crystal nephropathies.
Original paper ↗Read more →Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
To date, data simultaneously evaluating these parameters and interwoven relations on renal outcomes are scarce.
Original paper ↗Read more →The age-related changes of dietary phosphate responsiveness in plasma 1,25-dihydroxyvitamin D levels and renal Cyp27b1 and Cyp24a1 gene expression is associated with renal α-Klotho gene expression in mice
We found that 1,25-dihydroxyvitamin D levels in plasma were significantly lower in the high phosphate group than the low phosphate group for 1 and 2 month-old mice, but not 13 month-old mice.
Original paper ↗Read more →Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure
Impaired mineral homeostasis and inflammation are hallmarks of chronic kidney disease (CKD), yet the underlying mechanisms of electrolyte regulation during CKD are still unclear.
Original paper ↗Read more →Ethnic differences in parathyroid hormone secretion and mineral metabolism in response to oral phosphate administration
The induced changes (%) in PTH and markers of mineral and bone metabolism after 2 h and over 5 days were examined.
Original paper ↗Read more →Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients
Serum calcium, phosphate, alkaline phosphatase,parathyroid hormone, FGF-23, 25(OH)D, 1,25(OH)2D and Fractional excretion of phosphorous were assessed and compared between the two groups, using SPSS software.
Original paper ↗Read more →The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis: clinical practice recommendation from the Pediatric Renal Nutrition Taskforce
Complications of mineral bone disease (MBD) are common and contribute to the high morbidity and mortality seen in children with CKD.
Original paper ↗Read more →Dietary phosphorus source reprograms the kidney-intestine axis to dictate calcium-phosphorus efficiency and egg production in aging hens
The decline in egg production in aging hens poses a significant challenge to sustainable poultry production.
Original paper ↗Read more →Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study
We aimed to describe the effect of the calcium phosphate product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.
Original paper ↗Read more →Klotho in the kidney distal convolution regulates urinary Klotho excretion and kidney calcium reabsorption, but not phosphate homeostasis
Klotho acts as a coreceptor for the phosphaturic hormone fibroblast growth factor-23 (FGF-23) and exists in both a membrane-bound and a soluble form (sKlotho) found in blood and urine.
Original paper ↗Read more →Positive association between serum calcium-phosphorus ratio and kidney stone prevalence: Analysis of NHANES data (2007 to 2020)
This study utilized data from the 2007 to 2020 National Health and Nutrition Examination Survey (NHANES), including a total of 34,122 participants.
Original paper ↗Read more →Reduced phosphorus intake throughout gestation and lactation of sows is mitigated by transcriptional adaptations in kidney and intestine
L diets led to an increase in CYP27B1 expression in the kidney compared to the H group and to an altered gene expression associated with lipid metabolism in the kidney and immune response in the jejunum.
Original paper ↗Read more →Coactivator-independent vitamin D receptor signaling causes severe rickets in mice, that is not prevented by a diet high in calcium, phosphate, and lactose
The vitamin D receptor (VDR) plays a critical role in the regulation of mineral and bone homeostasis.
Original paper ↗Read more →Consequences of a high phosphorus intake on mineral metabolism and bone remodeling in dependence of calcium intake in healthy subjects: a randomized placebo-controlled human intervention study
Renal calcium and magnesium excretion decreased significantly after eight weeks of P1000/Ca0 intervention compared to placebo.
Original paper ↗Read more →Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium
The prevalence of low: turnover bone disease (LTBD) in peritoneal dialysis (PD) patients is higher than in hemodialysis (HD) patients.
Original paper ↗Read more →PTH-Independent CaSR Inhibition with the Oral Calcilytic Encaleret Improves Calcium Homeostasis in Post-Surgical Hypoparathyroidism: A Phase 2 Open-Label Proof-of-Concept Trial
The calcium-sensing receptor (CaSR) maintains calcium homeostasis by regulating parathyroid hormone (PTH) secretion and directly modulating renal calcium reabsorption.
Original paper ↗Read more →The Preventive Impact of Chokeberry (Aronia melanocarpa L.) Extract Regarding the Disruption of Calcium and Phosphorus Homeostasis and Chosen Pathways of Its Regulation in an Animal Model of General Population Exposure to Cadmium
Low-level Cd treatment (1 mg/kg) caused only a temporary elevation in the serum PTH concentration and a decline in the concentration of CT.
Original paper ↗Read more →Original sources
View the verified primary source
View the verified primary source.
Publication details
View the verified primary source